Stress ulcers are stress-induced gastritis or gastropathy where the gastric and sometimes esophageal or duodenal mucosal barrier is disrupted secondary to a severe acute illness. It may present in the form of erosive gastritis ranging from asymptomatic superficial lesions, and occult gastrointestinal (GI) bleed to overt clinically significant GI bleeding. The stress ulcers secondary to systemic burns are known as Curling ulcer, stress ulcers in patients with acute traumatic brain injury are known as Cushing ulcer. The gastric body and fundus are common locations for stress ulcerations but can also be seen in antrum and duodenum.
The major risk factors for the development of stress ulcerations include:
The incidence of stress ulcer is not well known but is thought to almost always occur in severe acute illness. The most common presentation of stress ulceration is in the form of upper GI bleeding, and GI bleed secondary to stress ulcerations may range from 1.5% to 15% depending on whether or not patients received stress ulcer prophylaxis. The incidence of stress ulceration and its complications are known to be declining with the advent of active prophylaxis methods for the prevention of stress-related gastritis. Patients with GI bleeding secondary to stress ulceration have increased morbidity and mortality compared to those who do not have GI bleed. Hence stress ulcer prophylaxis has been the center of many randomized clinical trials. Very rarely (less than 1% of the times), stress ulcers can cause perforation and perforation related complications.
Stress ulceration results from damage to the mucosal barrier secondary to systemic stress resulting in multiple superficial erosions of the gastric mucosa. The possible pathological changes leading to ulceration can be an impaired mucosal barrier where the mucosal glycoprotein is denuded by increased concentrations of refluxed bile salts or uremic toxins due to a critical illness. Increased secretion of gastric acid in response to higher secretion of gastrin hormone in patients is also thought to be responsible for stress ulceration. However, this is more commonly seen in patients with acute neurological trauma than other stress-related diseases. Helicobacter pylori infection has also been associated with stress ulcers though the evidence is limited. There could be a subgroup of critical care patients who may present with overt GI bleeding without stress ulceration or stress-related mucosal damage (SRMD), such as a patient with variceal bleeds, vascular anomalies, or diverticulosis. Hence these GI bleeds may not respond adequately to stress ulcer prophylaxis (SUP) or antireflux therapy with proton pump inhibitors (PPI) or antihistaminic.
Patients with acute respiratory distress syndrome (ARDS) who receive positive pressure ventilation (PPV) for more than 3 days are especially susceptible to mucosal damage due to splanchnic hypo-perfusion, which is more pronounced at positive end-expiratory pressure (PEEP) levels of 15-20 cm of H2O.
The most common mode of presentation of stress ulcers is the onset of acute upper GI bleed like hematemesis or melena in a patient with acute critical illness. The patient may or may not have hemodynamic instability in the presence of bleeding, and most of these patients do have a drop in hemoglobin concentration requiring blood transfusions.
Before the diagnostic evaluation for stress ulceration, stabilization of the patients should take priority. Monitor the need for fluid resuscitation and blood transfusion and reversal of coagulopathy if needed. Esophagogastroduodenoscopy should be performed. Stress ulcers are seen as small superficial mucosal erosions or ulcerations in the gastric body and fundus.
Testing for H. pylori infection like urease breath test or stool antigen test can also be undertaken for refractory stress ulceration.
Management of stress-induced gastritis includes prompt identification and prevention of complications related to stress ulceration. The management can be divided into pharmacological and non-pharmacological interventions.
The nonpharmacological interventions include early enteral feeding, NG tube placement intravenous fluid resuscitation, blood transfusion, and reversal of coagulopathy by platelets transfusion or transfusion of fresh frozen plasma or cryoprecipitate.
The medical management of patients with stress ulcers is more or less similar to the management of peptic ulcer disease in general. The medication targeting acid peptic disease includes proton pump inhibitors, antihistaminic, and ulcer-healing drugs like sucralfate. Patients with overt GI bleeding from ulceration will require endoscopic evaluation and management of the stress ulcers. Endoscopic therapies may include epinephrine injection, electro-cauterization, or clipping of the bleeding vessels. Bleeding ulcers refractory to localized endoscopic treatment may need embolization of the culprit vessel or rarely surgical intervention as a last resort. Surgical interventions are commonly indicated for patients with refractory bleeding despite endoscopic or angiographic treatment or patients with unstable hemodynamics to undergo endoscopic or angiographic procedures. Surgeries are performed as an ultimate life-saving approach.
Sometimes the ulcers can be deep enough to cause perforation of the gastric wall leading to acute peritonitis requiring urgent laparotomy. In comparison to other forms of stress ulcerations, perforations are most likely to happen with Cushing and Curling ulcers as they tend to be deep and can cause extensive necrosis. Mortality without surgical intervention in these patients who develop free wall GI perforation is almost 100%.
Patients with stress ulceration usually have poor prognosis secondary to the underlying critical illness. Moreover, GI bleeds in these patients secondary to stress-related mucosal disease is independently associated with increased morbidity and mortality. More often, these patients are too unstable for advanced endoscopic or surgical procedures to suppress GI bleed, leading to worse outcomes. Hence, aggressive prophylactic measures for the appropriate patient population at risk of developing stress ulceration remains the cornerstone in the management of stress-induced gastropathy.
Stress ulcer prophylaxis (SUP) has been a center of debate for various national and international societies of critical care. SUP has shown to be of benefit in preventing GI bleeding related to stress ulceration, but the guidelines regarding the indications, drug selection, and duration of SUP are not clear.
Surviving sepsis campaign recommends SUP for patients on mechanical ventilation for more than 48 hours and patients with coagulopathy. The other indications for SUP include sepsis and septic shock, severe burn injuries, use of high dose steroids, and neurological trauma. Surviving sepsis campaign recommends the use of PPI over antihistamines for SUP. Even though multiple studies have challenged the superiority of one over the other, PPIs are the most common agents used in the ICU and burn unit as SUP. Sucralfate an ulcer-healing drug can also be used for SUP, it is shown to be less effective than PPI ad histamine blockers but safer regarding adverse reactions. Cytoprotective agents like prostaglandin analogs (misoprostol) can also be used for SUP. They not only suppress acid secretion via a cyclic AMP pathway but also enhance the mucosal barrier of the gastric epithelium. However, they are still under investigation and lack adequate evidence for use in SUP. The adverse effects of the frequent use of PPIs in this population, including but not limited to, Clostridium difficile-associated diarrhea, pneumonia, and adverse drug interactions.
The duration of stress ulcer prophylaxis is usually for the period of critical illness or the duration of mechanical ventilation, and sometimes it can be continued until the patient begins to tolerate the oral diet.
The major part of the management of stress ulcers is its prevention in the critical care population with high-risk factors as the outcomes associated with stress-induced gastritis, and the GI bleed is worse but preventable. An interprofessional team consisting of the critical care nurse and critical care specialist physician working towards minimizing the risk will provide the best patient outcomes. Pharmacists evaluate medications use for prophylaxis and check for drug-drug interactions. Nursing staff monitor patients and update the team when the patient status changes. [Level 5]
|||Prevalence and outcome of gastrointestinal bleeding and use of acid suppressants in acutely ill adult intensive care patients., Krag M,Perner A,Wetterslev J,Wise MP,Borthwick M,Bendel S,McArthur C,Cook D,Nielsen N,Pelosi P,Keus F,Guttormsen AB,Moller AD,Møller MH,, Intensive care medicine, 2015 May [PubMed PMID: 25860444]|
|||Siddiqui F,Ahmed M,Abbasi S,Avula A,Siddiqui AH,Philipose J,Khan HM,Khan TMA,Deeb L,Chalhoub M, Gastrointestinal Bleeding in Patients With Acute Respiratory Distress Syndrome: A National Database Analysis. Journal of clinical medicine research. 2019 Jan; [PubMed PMID: 30627277]|
|||HANS SELYE 70 YEARS LATER: STEROIDS, STRESS ULCERS & H. PYLORI., Szabó S,, Ideggyogyaszati szemle, 2014 Mar 30 [PubMed PMID: 26118247]|
|||Incidence and risk factors for gastrointestinal bleeding among patients admitted to medical intensive care units., Kumar S,Ramos C,Garcia-Carrasquillo RJ,Green PH,Lebwohl B,, Frontline gastroenterology, 2017 Jul [PubMed PMID: 28839905]|
|||Marker S,Perner A,Wetterslev J,Barbateskovic M,Jakobsen JC,Krag M,Granholm A,Anthon CT,Møller MH, Stress ulcer prophylaxis versus placebo or no prophylaxis in adult hospitalised acutely ill patients-protocol for a systematic review with meta-analysis and trial sequential analysis. Systematic reviews. 2017 Jun 24; [PubMed PMID: 28646925]|
|||Thomas G Orr Memorial Lecture. Pathogenesis, prophylaxis, and treatment of stress gastritis., Cheung LY,, American journal of surgery, 1988 Dec [PubMed PMID: 3059833]|
|||Mutlu GM,Mutlu EA,Factor P, GI complications in patients receiving mechanical ventilation. Chest. 2001 Apr; [PubMed PMID: 11296191]|
|||Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012., Dellinger RP,Levy MM,Rhodes A,Annane D,Gerlach H,Opal SM,Sevransky JE,Sprung CL,Douglas IS,Jaeschke R,Osborn TM,Nunnally ME,Townsend SR,Reinhart K,Kleinpell RM,Angus DC,Deutschman CS,Machado FR,Rubenfeld GD,Webb S,Beale RJ,Vincent JL,Moreno R,, Intensive care medicine, 2013 Feb [PubMed PMID: 23361625]|
|||Ritchie WP Jr, Role of bile acid reflux in acute hemorrhagic gastritis. World journal of surgery. 1981 Mar; [PubMed PMID: 6972675]|
|||Stress-related mucosal disease: incidence of bleeding and the role of omeprazole in its prophylaxis., Amaral MC,Favas C,Alves JD,Riso N,Riscado MV,, European journal of internal medicine, 2010 Oct [PubMed PMID: 20816590]|
|||Enquist IF,Karlson KE,Dennis C,Fierst SM,Shaftan GW, Statistically valid ten-year comparative evaluation of three methods of management of massive gastroduodenal hemorrhage. Annals of surgery. 1965 Oct; [PubMed PMID: 5319395]|
|||Kanchan T,Geriani D,Savithry KS, Curling's ulcer - have these stress ulcers gone extinct? Burns : journal of the International Society for Burn Injuries. 2015 Feb; [PubMed PMID: 25440842]|
|||Bleeding complications in critically ill patients with liver cirrhosis., Cho J,Choi SM,Yu SJ,Park YS,Lee CH,Lee SM,Yim JJ,Yoo CG,Kim YW,Han SK,Lee J,, The Korean journal of internal medicine, 2016 Mar [PubMed PMID: 26805633]|
|||Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis., Pimentel M,Roberts DE,Bernstein CN,Hoppensack M,Duerksen DR,, The American journal of gastroenterology, 2000 Oct [PubMed PMID: 11051351]|
|||Stress Ulcer Prophylaxis in Neurocritical Care., Barletta JF,Mangram AJ,Sucher JF,Zach V,, Neurocritical care, 2017 Sep 19 [PubMed PMID: 28929324]|
|||Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial., Krag M,Perner A,Wetterslev J,Wise MP,Borthwick M,Bendel S,Pelosi P,Keus F,Guttormsen AB,Schefold JC,Møller MH,, Trials, 2016 Apr 19 [PubMed PMID: 27093939]|
|||Stress Ulcer Prophylaxis., Barletta JF,Bruno JJ,Buckley MS,Cook DJ,, Critical care medicine, 2016 Jul [PubMed PMID: 27163192]|